COLD AGGLUTININ DISEASE (CAD) IS
 ABOUT MORE THAN AVOIDING THE COLD,

  CHRONIC HEMOLYSIS
   CAN HAVE SEVERE
    CONSEQUENCES

CAD is a rare type of autoimmune hemolytic anemia that could put patients at risk1-3

CAD can be debilitating and patients are faced with the threat of severe events.2,3 Learn more about the symptoms they live with, the risks they face, and the data that highlight the seriousness of CAD.

Icon of question mark

Patients are burdened
by more than
just anemia

Icon of checklist

Understand criteria
to diagnose CAD
in patients

Icon of exclamation point

CAD can
impact patients'
lives

Sanofi Genzyme is committed to CAD awareness

CAD=Cold Agglutinin Disease.
References: 1. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12(5):361-370. 2. Broome CM, Cunningham JM, Mullins M, et al. Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort. Poster presented at: 59th Annual Meeting and Exposition of the American Society of Hematology Conference (ASH); December 9-12, 2017; Atlanta, GA. Abstract 928. 3. Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839-848.